Azzad Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-21,227
| Closed | -$1.65M | – | 339 |
|
|
2025
Q3 | $1.65M | Buy |
21,227
+16,296
| +330% | +$1.27M | 0.16% | 186 |
|
|
2025
Q2 | $386K | Buy |
+4,931
| New | +$368K | 0.04% | 280 |
|
|
2025
Q1 | – | Sell |
-8,135
| Closed | -$602K | – | 308 |
|
|
2024
Q4 | $602K | Sell |
8,135
-46,470
| -85% | -$3.25M | 0.12% | 143 |
|
|
2024
Q3 | $3.6M | Sell |
54,605
-602
| -1% | -$43.7K | 0.4% | 75 |
|
|
2024
Q2 | $5.1M | Sell |
55,207
-213
| -0.4% | -$18.9K | 0.6% | 27 |
|
|
2024
Q1 | $5.3M | Sell |
55,420
-41
| -0.1% | -$3.44K | 0.62% | 32 |
|
|
2023
Q4 | $4.23M | Buy |
55,461
+1,421
| +3% | +$98.9K | 0.54% | 44 |
|
|
2023
Q3 | $3.74M | Buy |
54,040
+5,291
| +11% | +$425K | 0.53% | 50 |
|
|
2023
Q2 | $4.6M | Buy |
48,749
+69
| +0.1% | +$6K | 0.62% | 34 |
|
|
2023
Q1 | $4.03M | Buy |
48,680
+319
| +0.7% | +$25.1K | 0.57% | 42 |
|
|
2022
Q4 | $3.61M | Sell |
48,361
-11,803
| -20% | -$910K | 0.57% | 41 |
|
|
2022
Q3 | $4.74M | Buy |
60,164
+460
| +0.8% | +$44.3K | 0.48% | 59 |
|
|
2022
Q2 | $5.24M | Buy |
59,704
+17,152
| +40% | +$1.78M | 0.52% | 47 |
|
|
2022
Q1 | $5.01M | Buy |
42,552
+885
| +2% | +$99.3K | 0.72% | 17 |
|
|
2021
Q4 | $5.4M | Buy |
41,667
+138
| +0.3% | +$16.1K | 0.72% | 18 |
|
|
2021
Q3 | $4.7M | Buy |
41,529
+429
| +1% | +$49K | 0.69% | 20 |
|
|
2021
Q2 | $4.26M | Buy |
41,100
+352
| +0.9% | +$33.2K | 0.63% | 25 |
|
|
2021
Q1 | $3.41M | Buy |
40,748
+290
| +0.7% | +$24.5K | 0.57% | 40 |
|
|
2020
Q4 | $3.69M | Buy |
40,458
+2,502
| +7% | +$208K | 0.67% | 29 |
|
|
2020
Q3 | $3.03M | Buy |
37,956
+21,098
| +125% | +$1.65M | 0.63% | 40 |
|
|
2020
Q2 | $1.17M | Buy |
16,858
+352
| +2% | +$25K | 0.27% | 136 |
|
|
2020
Q1 | $1.04M | Sell |
16,506
-50,361
| -75% | -$3.63M | 0.3% | 121 |
|
|
2019
Q4 | $2.43M | Buy |
66,867
+78
| +0.1% | +$6.09K | 0.29% | 122 |
|
|
2019
Q3 | $2.35M | Buy |
66,789
+30,390
| +83% | +$2.13M | 0.29% | 122 |
|
|
2019
Q2 | $2.24M | Buy |
+36,399
| New | +$2.2M | 0.62% | 37 |
|
|
2019
Q1 | – | Sell |
-36,135
| Closed | -$1.84M | – | 304 |
|
|
2018
Q4 | $1.84M | Sell |
36,135
-1,053
| -3% | -$53.3K | 0.62% | 35 |
|
|
2018
Q3 | $2.16M | Sell |
37,188
-174
| -0.5% | -$8.51K | 0.58% | 37 |
|
|
2018
Q2 | $1.81M | Buy |
37,362
+17,535
| +88% | +$818K | 0.52% | 51 |
|
|
2018
Q1 | $922K | Buy |
19,827
+2,265
| +13% | +$98.4K | 0.28% | 139 |
|
|
2017
Q4 | $660K | Buy |
17,562
+5,859
| +50% | +$215K | 0.21% | 169 |
|
|
2017
Q3 | $426K | Buy |
+11,703
| New | +$446K | 0.14% | 218 |
|
Other funds holding EW
Azzad Asset Management's EW Position: Q4 2025 in Review
Azzad Asset Management sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 21,227 shares — an estimated $1.65M sold.
Azzad Asset Management first reported a position in EW in Q3 2017 and held it in 31 quarters. The position peaked at $5.4M in Q4 2021. 1,314 funds tracked by Wall St. Rank hold EW as of Q4 2025.
- Azzad Asset Management reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
- Azzad Asset Management sold 21,227 Edwards Lifesciences shares in Q4 2025, an estimated $1.65M.
- Azzad Asset Management first reported a position in Edwards Lifesciences in Q3 2017 and held it in 31 quarters.
- Azzad Asset Management's Edwards Lifesciences position peaked at $5.4M in Q4 2021.
- 1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.
Based on Azzad Asset Management's 13F filing for Q4 2025, filed 21 Jan 2026.